Market Overview:
The global prostate cancer drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of prostate cancer, technological advancements in the field of prostate cancer treatment, and rising awareness about prostate cancer. The global prostate cancer drugs market is segmented on the basis of type into hormonal therapy, chemotherapy, immunotherapy, and targeted therapy. The hormonal therapy segment is expected to account for the largest share of the global market in 2018. This segment is projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030 due to increasing use of hormone therapies for treating advanced-stage prostate cancers. On the basis of application, clinics are expected to account for majority share (55%)of revenue generated by sales o fprostate cancer drugs globally by 2030 end .
Product Definition:
Prostate cancer drugs are used to treat prostate cancer. Prostate cancer is the most common type of cancer in men. The prostate is a gland located below the bladder that helps produce semen. Cancer begins when cells in the body start to grow out of control. Prostate cancer drugs may be used to shrink tumors, stop their spread, or relieve symptoms caused by the tumor such as pain or difficulty urinating.
Hormonal Therapy:
Hormonal therapy is a form of medical treatment that involves the use of hormones for treating cancer. Hormone therapy includes various types such as Androgen Deprivation Therapy (ADT), Luteinizing Hormone-Releasing Hormone (LHRH) agonist, Luteinizing Hormone-Releasing Hormone Antagonist (THR), and anti-androgen.
Chemotherapy:
Chemotherapy is the use of drugs or chemical agents to treat cancer. Chemotherapies are used to stop or slow down the growth of cancer cells. They can also make the tumors shrink faster than they would normally do. Some chemotherapies can kill all (or most) tumor cells while others just slow down their growth.
Application Insights:
The others application segment held the largest share of over 70.0% in 2017. This is owing to the increasing prevalence of other prostate cancer applications such as Prostate Cancer Canada clinics, hospitals and others. The clinics application segment is expected to grow at a lucrative CAGR during the forecast period due to an increase in awareness about early diagnosis and availability of treatment options for PCA at low costs compared to hospitals or other medical centers.
Hospitals are estimated to be one of the fastest-growing segments owing primarily because they offer advanced care with better infrastructure, equipment, experienced staff and world-class treatments that exceed patient expectations while reducing costs significantly compared with conventional therapies or surgeries performed in primary healthcare settings (family doctors offices).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and availability of healthcare infrastructure are some factors driving the growth of this regional market. In addition, rising incidence rates and increasing prevalence of other chronic diseases such as diabetes is expected to boost the demand for prostate cancer drugs in North America over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to an increase in disposable income levels coupled with a rise in consumer awareness regarding early diagnosis and treatment options for various cancers such as prostate cancer. Moreover, government initiatives aimed at improving healthcare facilities across emerging countries are expected to fuel industry expansion during the same period (2018-2030). For instance, according to data published by WHO (2016), Japan ranks first among Asian countries with respect to life expectancy rate at birth; it has been observed that Japanese women can expect 71 years of life while men can expect 75 years (as comparedto 65 years old recorded 50 years ago).
Growth Factors:
- Increasing incidence of prostate cancer
- Growing awareness about prostate cancer and its treatment options
- Rising demand for better and more effective prostate cancer drugs
- Technological advancements in the field of prostate cancer drugs development and research
- Availability of government funding for research on prostate cancer drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostate Cancer Drugs Market Research Report
By Type
Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy
By Application
Clinics, Hospitals, Others
By Companies
AbbVie, Astellas Pharma, Astra Zeneca, Johnson & Johnson, Sanofi, GlaxoSmithKline, Merck Group, Novartis, Amgen, Bayer HealthCare, Ferring Pharmaceutical, Janssen Pharmaceuticals, Endo Pharmaceuticals, BMS, Takeda Pharmaceuticals, Northwest Biotherapeutics, Teva Pharmaceutical, Boehringer Ingelheim, Foresee Pharmaceuticals, Tokai Pharmaceuticals, Spectrum Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
194
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Prostate Cancer Drugs Market Report Segments:
The global Prostate Cancer Drugs market is segmented on the basis of:
Types
Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinics, Hospitals, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Astellas Pharma
- Astra Zeneca
- Johnson & Johnson
- Sanofi
- GlaxoSmithKline
- Merck Group
- Novartis
- Amgen
- Bayer HealthCare
- Ferring Pharmaceutical
- Janssen Pharmaceuticals
- Endo Pharmaceuticals
- BMS
- Takeda Pharmaceuticals
- Northwest Biotherapeutics
- Teva Pharmaceutical
- Boehringer Ingelheim
- Foresee Pharmaceuticals
- Tokai Pharmaceuticals
- Spectrum Pharmaceuticals
Highlights of The Prostate Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hormonal Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- By Application:
- Clinics
- Hospitals
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostate Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There are many prostate cancer drugs available to treat the disease. These medications can help to shrink or stop the growth of tumors in the prostate, and may also improve symptoms such as difficulty urinating, fatigue, and pain. Some common prostate cancer drugs include:nnAndrogen deprivation therapy (ADT) u2013 This is a type of treatment that uses a combination of hormones to stop or slow the growth of tumors in the prostate. ADT can be given as an injection every day for several months or continuously through a pump over several years. Side effects from ADT may include hot flashes, mood changes, decreased sex drive, and infertility.nnSurgery u2013 Surgery is often used as first line treatment for advanced prostate cancer because it has high rates of success when treating localized cancersous tumors (those that have not spread). Surgery may involve removing part or all of the tumor using either open surgery (where parts of your body are exposed) or robotic surgery (which uses robots to perform surgical procedures). After surgery there is usually a period where you must take antibiotics to prevent infection from spreading into your wound. Side effects from surgery vary depending on which part(s) are removed but can often include urinary problems and sexual dysfunction due to nerve damage caused by radiation therapy following surgery
Some of the major players in the prostate cancer drugs market are AbbVie, Astellas Pharma, Astra Zeneca, Johnson & Johnson, Sanofi, GlaxoSmithKline, Merck Group, Novartis, Amgen, Bayer HealthCare, Ferring Pharmaceutical, Janssen Pharmaceuticals, Endo Pharmaceuticals, BMS, Takeda Pharmaceuticals, Northwest Biotherapeutics, Teva Pharmaceutical, Boehringer Ingelheim, Foresee Pharmaceuticals, Tokai Pharmaceuticals, Spectrum Pharmaceuticals.
The prostate cancer drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Prostate Cancer Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Prostate Cancer Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Prostate Cancer Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Prostate Cancer Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Prostate Cancer Drugs Market Size & Forecast, 2018-2028
4.5.1 Prostate Cancer Drugs Market Size and Y-o-Y Growth
4.5.2 Prostate Cancer Drugs Market Absolute $ Opportunity
Chapter 5 Global Prostate Cancer Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Prostate Cancer Drugs Market Size Forecast by Type
5.2.1 Hormonal Therapy
5.2.2 Chemotherapy
5.2.3 Immunotherapy
5.2.4 Targeted Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Prostate Cancer Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Prostate Cancer Drugs Market Size Forecast by Applications
6.2.1 Clinics
6.2.2 Hospitals
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Prostate Cancer Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Prostate Cancer Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Prostate Cancer Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Prostate Cancer Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Prostate Cancer Drugs Market Size Forecast by Type
9.6.1 Hormonal Therapy
9.6.2 Chemotherapy
9.6.3 Immunotherapy
9.6.4 Targeted Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Prostate Cancer Drugs Market Size Forecast by Applications
9.10.1 Clinics
9.10.2 Hospitals
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Prostate Cancer Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Prostate Cancer Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Prostate Cancer Drugs Market Size Forecast by Type
10.6.1 Hormonal Therapy
10.6.2 Chemotherapy
10.6.3 Immunotherapy
10.6.4 Targeted Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Prostate Cancer Drugs Market Size Forecast by Applications
10.10.1 Clinics
10.10.2 Hospitals
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Prostate Cancer Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Prostate Cancer Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Prostate Cancer Drugs Market Size Forecast by Type
11.6.1 Hormonal Therapy
11.6.2 Chemotherapy
11.6.3 Immunotherapy
11.6.4 Targeted Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Prostate Cancer Drugs Market Size Forecast by Applications
11.10.1 Clinics
11.10.2 Hospitals
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Prostate Cancer Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Prostate Cancer Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Prostate Cancer Drugs Market Size Forecast by Type
12.6.1 Hormonal Therapy
12.6.2 Chemotherapy
12.6.3 Immunotherapy
12.6.4 Targeted Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Prostate Cancer Drugs Market Size Forecast by Applications
12.10.1 Clinics
12.10.2 Hospitals
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Prostate Cancer Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Prostate Cancer Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Prostate Cancer Drugs Market Size Forecast by Type
13.6.1 Hormonal Therapy
13.6.2 Chemotherapy
13.6.3 Immunotherapy
13.6.4 Targeted Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Prostate Cancer Drugs Market Size Forecast by Applications
13.10.1 Clinics
13.10.2 Hospitals
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Prostate Cancer Drugs Market: Competitive Dashboard
14.2 Global Prostate Cancer Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Astellas Pharma
14.3.3 Astra Zeneca
14.3.4 Johnson & Johnson
14.3.5 Sanofi
14.3.6 GlaxoSmithKline
14.3.7 Merck Group
14.3.8 Novartis
14.3.9 Amgen
14.3.10 Bayer HealthCare
14.3.11 Ferring Pharmaceutical
14.3.12 Janssen Pharmaceuticals
14.3.13 Endo Pharmaceuticals
14.3.14 BMS
14.3.15 Takeda Pharmaceuticals
14.3.16 Northwest Biotherapeutics
14.3.17 Teva Pharmaceutical
14.3.18 Boehringer Ingelheim
14.3.19 Foresee Pharmaceuticals
14.3.20 Tokai Pharmaceuticals
14.3.21 Spectrum Pharmaceuticals
